Delcath Systems, Inc. (OTCMKTS:DCTH) CFO Barbra Keck acquired 7,399 shares of the stock in a transaction that occurred on Friday, September 28th. The stock was purchased at an average price of $1.75 per share, for a total transaction of $12,948.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Delcath Systems stock traded down $0.06 on Thursday, hitting $0.42. 133,779 shares of the company were exchanged, compared to its average volume of 211,588. Delcath Systems, Inc. has a 1-year low of $0.32 and a 1-year high of $1,750.00.
Delcath Systems (OTCMKTS:DCTH) last issued its earnings results on Wednesday, August 15th. The company reported ($4.18) earnings per share for the quarter. The firm had revenue of $0.86 million during the quarter.
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.